ArticleFrontiers in oncology2025
Characteristic metabolite profile of 10 colorectal cancer-related bacteria.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lactobacillus and Tryptophan Supplementation Improve Renal Function and are Associated with Metabolomic Alterations in a Mouse Model of Chronic Kidney Disease.Probiotics and antimicrobial proteins · 2026Article
- Hepatic SNHG9 links gut microbiota to liver protection in drug-induced liver injury.Nature communications · 2026Article
- Taxonomy, carcinogenic mechanisms, and advanced molecular diagnosis of Fusobacterium nucleatum in colorectal cancer: from bench to clinical practice.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor metabolomics of colorectal cancer (CRC) is significantly different from normal tissues, due to nutrient deprivation, metabolite accumulation, acidity and hypoxia. Besides, gut microbiota has been confirmed to affect the progression of CRC. Microbiota metabolites might participate in the metabolic reprogramming of CRC cells and further regulate tumor microenvironment. Method: 10 CRC-related strains are cultured in vitro (10 replicates per bacterium), including Enterotoxic Escherichia coli (ETEC), Peptostreptococcus anaerobius (Pa), Fusobacterium necroporum (Fne), Fusobacterium nucleatum (Fn), Lactobacillus plantarum (Lp), Lactobacillus acidophilus (La), Lactobacillus casei (Lc), Lactobacillus rhamnosus gg (LGG), Bifidobacterium bifidum (Bbi), Bifidobacterium Breve (Bbr). Bacterial culture supernatant is subjected to gas chromatography-mass spectrometry. Result: The 10 CRC-related strains have characteristic metabolite profiles, mainly referring to specific saccharides, amino acids, bile acids, polyamines and bioactive compounds. Saccharides and organic acids increase significantly in Conclusion: The 10 CRC-related strains possess significantly different metabolites and metabolic pathways. Specific metabolites and corresponding metabolic pathways might explain microbial CRC-promoting or -suppressing mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.